GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » 5-Year RORE %

China Resources Pharmaceutical Group (HKSE:03320) 5-Year RORE % : 6.11% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. China Resources Pharmaceutical Group's 5-Year RORE % for the quarter that ended in Dec. 2023 was 6.11%.

The industry rank for China Resources Pharmaceutical Group's 5-Year RORE % or its related term are showing as below:

HKSE:03320's 5-Year RORE % is ranked better than
54.13% of 909 companies
in the Drug Manufacturers industry
Industry Median: 3.13 vs HKSE:03320: 6.11

China Resources Pharmaceutical Group 5-Year RORE % Historical Data

The historical data trend for China Resources Pharmaceutical Group's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group 5-Year RORE % Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 0.81 2.68 -0.13 6.11

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.91 -0.13 -4.61 6.11

Competitive Comparison of China Resources Pharmaceutical Group's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's 5-Year RORE % falls into.



China Resources Pharmaceutical Group 5-Year RORE % Calculation

China Resources Pharmaceutical Group's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.667-0.529 )/( 2.926-0.666 )
=0.138/2.26
=6.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


China Resources Pharmaceutical Group  (HKSE:03320) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


China Resources Pharmaceutical Group 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines